Sex: U
Vaccine: COVID19
Symptoms: No adverse event, Poor quality product administered, Product temperature excursion issue
Clinical narrative: patient received dose of Moderna vaccine post excursion; patient received dose of Moderna vaccine post excursion; No adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (patient received dose of Moderna vaccine post excursion), POOR QUALITY PRODUCT ADMINISTERED (patient received dose of Moderna vaccine post excursion) and NO ADVERSE EVENT (No adverse event) in a  patient of an unknown age and gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (patient received dose of Moderna vaccine post excursion), POOR QUALITY PRODUCT ADMINISTERED (patient received dose of Moderna vaccine post excursion) and NO ADVERSE EVENT (No adverse event). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (patient received dose of Moderna vaccine post excursion), POOR QUALITY PRODUCT ADMINISTERED (patient received dose of Moderna vaccine post excursion) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for PRODUCT TEMPERATURE EXCURSION ISSUE (patient received dose of Moderna vaccine post excursion) and POOR QUALITY PRODUCT ADMINISTERED (patient received dose of Moderna vaccine post excursion).    No Concomitant products reported.  It was reported that patient received the dose of Moderna vaccine post excursion.  No treatment products reported.  This case contains information for the 13th of 19 patients reported by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2023-706941, US-MODERNATX, INC.-MOD-2023-706968, US-MODERNATX, INC.-MOD-2023-706964, US-MODERNATX, INC.-MOD-2023-706950, US-MODERNATX, INC.-MOD-2023-706949, US-MODERNATX, INC.-MOD-2023-706954, US-MODERNATX, INC.-MOD-2023-706967, US-MODERNATX, INC.-MOD-2023-707010, US-MODERNATX, INC.-MOD-2023-707009, US-MODERNATX, INC.-MOD-2023-707006, US-MODERNATX, INC.-MOD-2023-707012, US-MODERNATX, INC.-MOD-2023-707014 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-706941:Patient 1 of 19 US-MODERNATX, INC.-MOD-2023-706968:Patient 19 of 19 US-MODERNATX, INC.-MOD-2023-706964:Patient 6 of 19 US-MODERNATX, INC.-MOD-2023-706950:Patient 17 of 19 US-MODERNATX, INC.-MOD-2023-706949:Patient 4 of 19 US-MODERNATX, INC.-MOD-2023-706954:Patient 14 of 19 US-MODERNATX, INC.-MOD-2023-706967:Patient 16 of 19 US-MODERNATX, INC.-MOD-2023-707010:Patient 8 of 19 US-MODERNATX, INC.-MOD-2023-707009:Patient 5 of 19 US-MODERNATX, INC.-MOD-2023-707006:Patient 15 of 19 US-MODERNATX, INC.-MOD-2023-707012:Patient 15 of 19 US-MODERNATX, INC.-MOD-2023-707014:Patient 18 of 19